Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Exec On COVID-19 Vaccine: Moving At High Speed But No Safety Compromises

'Different Way Of Working'

Executive Summary

J&J executive emphasizes that fast-tracked development of COVID-19 vaccines does not come with any corners cut around safety. Indian partner Biological E also outlines the complexities in manufacturing and believes that the candidates from J&J, AstraZeneca and others will be more suitable in profile and price terms to contain the pandemic globally.

You may also be interested in...



Watch This Space: Reliance Advances Protein-Based COVID-19 Vaccine

Reliance Life Sciences, part of India’s largest private sector enterprise with a growing engagement in healthcare, is progressing an early-stage COVID-19 vaccine. A top executive underscores the potential to manufacture at scale and provide the protein-based candidate at a competitive price.

Expanded Distribution For COVID Vaccines Will Boost Options – And Logistical Complications

Operation Warp Speed officials eye the Moderna vaccine and upcoming one-shot Janssen product to widen the immunization campaign’s reach, but more products also could bring more problems.

Coronavirus Update: SK Bioscience, Biological E, DongWha And Celltrion Report Progress

SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143524

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel